Henry Schein (NASDAQ:HSIC) Cut to “Buy” at Wall Street Zen

Wall Street Zen lowered shares of Henry Schein (NASDAQ:HSIC) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

Other research analysts have also issued reports about the company. Wells Fargo & Company raised their price target on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. UBS Group boosted their price objective on Henry Schein from $79.00 to $87.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Morgan Stanley increased their target price on Henry Schein from $58.00 to $61.00 and gave the stock an “underweight” rating in a research note on Wednesday, February 25th. Mizuho raised their target price on Henry Schein from $81.00 to $88.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. lifted their target price on Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $85.58.

Henry Schein Price Performance

Henry Schein stock opened at $74.61 on Friday. The company’s 50 day simple moving average is $78.13 and its 200-day simple moving average is $72.93. The company has a market capitalization of $8.56 billion, a price-to-earnings ratio of 22.82, a price-to-earnings-growth ratio of 2.24 and a beta of 0.87. Henry Schein has a 1 year low of $60.56 and a 1 year high of $89.29. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The firm had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same period in the prior year, the business posted $1.19 EPS. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities research analysts expect that Henry Schein will post 4.74 earnings per share for the current year.

Insider Buying and Selling

In other Henry Schein news, Director Kurt P. Kuehn sold 2,844 shares of the company’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total transaction of $224,562.24. Following the sale, the director owned 15,420 shares in the company, valued at $1,217,563.20. This represents a 15.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Philip A. Laskawy sold 2,844 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $80.36, for a total value of $228,543.84. Following the sale, the director owned 21,961 shares in the company, valued at approximately $1,764,785.96. This trade represents a 11.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 104,556 shares of company stock valued at $8,476,351 in the last three months. 1.14% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Henry Schein

A number of institutional investors and hedge funds have recently made changes to their positions in HSIC. AQR Capital Management LLC raised its holdings in Henry Schein by 47.3% in the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after acquiring an additional 9,756 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Henry Schein by 1.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after acquiring an additional 229 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Henry Schein in the 1st quarter valued at approximately $676,000. ProShare Advisors LLC increased its position in shares of Henry Schein by 9.8% in the 2nd quarter. ProShare Advisors LLC now owns 21,966 shares of the company’s stock valued at $1,605,000 after purchasing an additional 1,956 shares during the last quarter. Finally, Allworth Financial LP raised its holdings in shares of Henry Schein by 39.2% in the 2nd quarter. Allworth Financial LP now owns 1,640 shares of the company’s stock valued at $120,000 after purchasing an additional 462 shares in the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.